



6/27/2016  
Revised 9/16/16

Dear Manufacturers,

I am writing on behalf of WellSpace Health (CHC 12872-00) (the "Organization"), to inform you that the Organization recently underwent an audit by the Health Resources and Services Administration ("HRSA") of our compliance with the 340B Drug Pricing Program ("340B Program") requirements.

As background, WellSpace Health qualified for the 340b Program on April 1, 2009 as an FQHC located at 1820 J Street, Sacramento, California and has participated in the 340b Program since April 1, 2009.

HRSA's audit revealed an issue with the Organization's compliance with the 340B Program requirements making us responsible for repayment as a result of the following finding:

1. WellSpace Health dispensed 340b drugs to ineligible individuals as prohibited by section 340B (a) (5) (B).

The Organization identified the affected manufacturer and repaid the sum due the manufacturer under cover of letter dated September 21, 2015. HRSA was notified of the repayment by letter dated October 1, 2015, which contained confirmation that the amount repaid was acceptable to the affected manufacturer .

If any other manufacturers have not received notification from the Organization and believe repayment may be owed for the violation described in this letter, or if you have any questions or comments regarding the violation described in this letter, please contact:

Mr. A. Jonathan Porteus, Chief Executive Officer  
WellSpace Health  
1820 J Street, Sacramento, CA 95811-3010  
Telephone : (916) 313-8413 .

Sincerely,

 Nathan Porteus,   
Chief Executive Officer